MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/10428194.2024.2325636

Медицинская библиотека · Leukemia & lymphoma · 2024

Lenalidomide, rituximab (R2), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma.

Hill Brian T, Chen Yanwen, Jagadeesh Deepa, Dean Robert, Koc Omer, Boughan Kirsten, Cooper Brenda, Pohlman Brad, Caimi Paolo, Smith Mitchell R

СтатьяКлиническое исследование I фазыКлиническое исследование II фазыПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Lenalidomide and rituximab (R2) is an effective frontline treatment for patients with indolent B-cell non-Hodgkin lymphoma (iNHL). We investigated the safety and efficacy of addition of the proteasome inhibitor ixazomib to R2 for treatment of iNHL through a phase I/II clinical trial for high-risk patients. Twenty patients were enrolled, 18 were treated. The target dose of ixazomib 4 mg weekly was achieved during dose escalation. The most common treatment-related adverse events (AEs) were low grade gastrointestinal, rash, neuropathy, and myalgia/arthralgia. There were 33% grade 2 and 17% grade 3 infections. With median follow-up of 5.2 years, four patients discontinued treatment due to lymphoma progression. Best overall response rate (ORR) was 61.2% [55.6% CR, 5.6% PR): 22.2% had stable disease and 16.7% had disease progression. Kaplan-Meier estimates of progression free and overall survival (OS) were 73% and 87% at 36 months, respectively. R2 can safely be combined with ixazomib for treatment-naïve iNHL patients.

Для цитирования: Hill Brian T, Chen Yanwen, Jagadeesh Deepa, Dean Robert, Koc Omer, Boughan Kirsten, Cooper Brenda, Pohlman Brad, Caimi Paolo, Smith Mitchell R. Lenalidomide, rituximab (R2), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma.. Leukemia & lymphoma. 2024. DOI: 10.1080/10428194.2024.2325636.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.